Publikationen
1. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA-ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42(2):197-209.
2. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kuebler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. Journal of Nuclear Medicine 2015;56(11):1697-1705.
3. Afshar-Oromieh A, Kratochwil C, Eder M, Eisenhut M, Kopka K, Haberkorn U. Diagnosis of Recurrent Prostate Cancer with PSMA-Ligand PET/CT and Clinical Introduction of PSMA-based Radioligand Therapy (Rezidivdiagnostik des Prostatakarzinoms mit PSMA-Liganden PET/CT und die Initialen klinischen Erfahrungen mit der PSMA-basierten Radioligandentherapie). Nuklearmediziner 2015;38: 124-130.
4. Afshar-Oromieh A, Wolf MB, Kratochwil C, Giesel FL, Combs SE, Dimitrakopoulou-Strauss A, Gnirs R, Roethke MC, Schlemmer HP, Haberkorn U. Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro-Oncology 2015;17(2): 312-319.
5. Benesova M, Schaefer M, Bauder-Wuest U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine 2015;56(6): 914-920.
6. Dimitrakopoulou-Strauss A. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome. Future Oncology 2015;11(7): 1083-1091.
7. Doberstein K, Harter PN, Haberkorn U, Bretz NP, Arnold B, Carretero R, Moldenhauer G, Mittelbronn M, Altevogt P. Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT. Int J Cancer 2015;136(5): E326-E339. doi:10.1002/ijc. 29222. [Epub ahead of print].
8. Flechsig P, Choyke P, Kratochwil C, Warth A, Antoch G, Holland-Letz T, Rath D, Eichwald V, Huber PE, Kauczor HU, Haberkorn U, Giesel FL. Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer. Diagnostic and Interventional Radiology 2015;22(1):35-9.
9. Flechsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL. PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies. Seminars in Nuclear Medicine 2015;45(4): 268-281.
10. Flechsig,P, Kratochwil C, Warth A, Rath D, Eichwald V, Huber PE, Kauczor HU, Haberkorn U, Giesel FL. A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model. Molecular Imaging and Biology 2015 .
11. Flechsig P, Zechmann CM, Schreiweis J, Kratochwil C, Rath D, Schwartz LH, Schlemmer HP, Kauczor HU, Haberkorn U, Giesel FL. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET. European Journal of Radiology 2015;84(8): 1593-1600.
12. Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A. Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2015;84(8):1593-1600.
13. Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, Moltz JH, Afshar-Oromieh A, Choyke PL, Haberkorn U, Kratochwil C. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2015;42(12):1794-1800.
14. Haberkorn U, Kopka K, Hadaschik B. Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer. European Urology , 2015.
15. Hassel JC, Lee SB, Meiss F, Meier F, Dimitrakopoulou-Strauss A, Jaeger D, Enk AH. Vemurafenib and Impilimumab: a promising combination? Results of a 0case series. OncoImmunology , 2015.
16. Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, Kopka K, Babich JW, Haberkorn U. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. Journal of Nuclear Medicine 2015;56(2): 293-298.
17. Kratochwil C, Mavriopoulou E, Rath D, Afshar-Oromieh A, Apostolopoulos D, Haufe S, Mier W, Haberkorn U, Giesel FL. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015;59(1): 116-120.
18. Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier W, Haberkorn U, Giesel FL. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendo-crine Tumors. Molecular Imaging and Biology 2015;17(3): 313-318.
19. KratochwilC, Giesel FL. Radionuclide therapy of endocrtine-related cancer. Radiologe 2015;54(10): 1007-1015.
20. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, Kopka K, Haberkorn U. [(177)Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2015;42(6):987-988.
21. Larribere L, Wu H, Novak D, Galach M, Bernhardt M, Orouji E, Weina K, Knappe N, Sachpekidis C, Umansky L, Beckhove P, Umansky V, De Schepper S, Kaufmann D, Ballotti R, Bertolotto C, Utikal J. NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model. Pigment Cell and Melanoma Research 2015;28(4): 407-416.
22. Mena-Romano P, Cheng C, Glowa C, Peschke P, Pan L, Haberkorn U, Dimitrakoloulou-Strauss A, Karger CP. Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic 18F-FMISO-PET-CT and quantitative histology. American Journal of Nuclear Medicine and Molecular Imaging 2015;5(4): 348-362.
23. Rae C, Haberkorn U, Babich JW, Mairs RJ. Inhibition of Fatty Acid Synthase Sensitzizes Prostate Cancer Cells to Radiotherapy. Radiation Research 2015;184(5):482-93.
24. Sachpekidis C, Hillengass J, Goldschmidt H, Mosebach J, Pan L, Schlemmer HP, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. American Journal of Nuclear Medicine and Molecular Imaging 2015;5(5):469-478.
25. Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hasse ,JC. Predictive value of early F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. European Journal of Nuclear Medicine and Molecular Imaging 2015;42(3): 386-396.
26. Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A. 18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma: Patterns of Tracer Uptake and Correlation With Bone Marrow Plasma Cell Infiltration Rate. Clinical Nuclear Medicine 2015;40(6), e300-e307.
27. Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, Haberkorn U, Schlemmer HP, Delorme S, Dimitrakopoulou-Strauss A. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. American Journal of Nuclear Medicine and Molecular Imaging 2015;5(5), 479-492.
28. Sachpekidis C, Thieke C, Askoxylakis V, Nicolay NH, Huber PE, Thomas M, Dimitrakopoulou G, Debus J, Haberkorn U, Dimitrakopoulou-Strauss A. Combined use of 18F-FDG and 18F-FMISO in unresectable non-smal cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. American Journal of Nuclear Medicine and Molecular Imaging 2015;5(2):127-142.
29. Schoelch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M, Huber PE: Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget 2015;6(7): 4663-4676.
30. Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. F-18-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 1, CD010632, 2015.
31. Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, Afshar-Oromieh A, Debus J, Haberkorn U, Giesel FL. 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging; 2016;43(1)34-41. doi: 10.1007/s00259-015-3188-1 (Epub 2015).
32. Uhl P, Fricker G, Haberkorn U, Mier W. Radionuclides in drug development. Drug Discov Today 2015;20(2):198-208. pii: S1359-6446(14)00396-1. doi: 10.1016/j.drudis. 2014.09.027.
33. Weber T, Boetticher B, Mier W, Sauter M, Kraemer S, Leotta K, Keller A, Schlegelmilch A, Grosse-Hovest L, Jaeger D, Haberkorn U, Arndt MA, Krauss J. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab. European Journal of Nuclear Medicine and Molecular Imaging 2015.
34. Weber J, Haberkorn U, Mier W. Cancer stratification by molecular imaging. International Journal of Molecular Sciences 2015;16(3): 4918-4946.
35. Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bellò M, Rambaldi I, Tacchetti P, Hillengass J, Gamberi B, Pantani L, Magarotto V, Versari A, Offidani M, Zannetti B, Carobolante F, Balma M, Musto P, Rensi M, Mancuso K, Dimitrakopoulou-Strauss A, Chauviè S, Rocchi S, Fard N, Marzocchi G, Storto G, Ghedini P, Palumbo A, Fanti S, Cavo M. 18F-FDG PET/CT FOCAL, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 2015.
36. Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Boening G. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015.
Buchbeiträge
1. Wetzke M, Happle Ch, Giesel F, Zechmann Ch. Basics Bildgebende Verfahren. In: Basics Bildgebende Verfahren / Urban & Fischer, Elsevier Health Sciences, 2015.